1. Orphan drug development: an economically viable strategy for biopharma R&D;Meekings;Drug Discov. Today,2012
2. Meyers, Abbey S., President, February 18, 2000. National Organization for Rare Disorders (NORD). In: International Conference of Rare Diseases and Orphan Drugs, Spain.
3. Rodwell, C., Aymé, S., (Eds.), July 2014. “2014 Report on the State of the Art of Rare Disease Activities in Europe” .
4. Why rare diseases are an important medical and social issue;Schieppati;Lancet,2008
5. Incentives for orphan drug research and development in the United States;Seoane-Vazquez;Orphanet J. Rare Dis.,2008